Skip to content

Clinical trials

Esophageal Neoplasms trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Esophageal Neoplasms Phase: Not applicable Country / region: United States Clear all

92 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20041
20066
20081
20095
20104
20114
20121
20133
20142
20155
20168
20174
20186
20194
20206
20218
20224
20236
20244
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed43
Terminated17
Recruiting16
Unknown status6
Withdrawn4
Active, not recruiting4
Enrolling by invitation1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center5
Dartmouth-Hitchcock Medical Center4
Massachusetts General Hospital4
Mayo Clinic4
Stanford University4
Alliance for Clinical Trials in Oncology3
Case Comprehensive Cancer Center3
Dana-Farber Cancer Institute3
Duke University3
Washington University School of Medicine3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Esophageal Neoplasms92
Stomach Neoplasms29
Lung Neoplasms24
Pancreatic Neoplasms24
Colonic Neoplasms16
Carcinoma, Non-Small-Cell Lung14
Head and Neck Neoplasms14
Breast Neoplasms13
Liver Neoplasms13
Ovarian Neoplasms12

Trials

Showing 1 to 25 of 92. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.